REBEC

Go to main content [1]
Go to main menu [2]
Enable hight contrast [3]

-

-

-

-

-

Public trial

Trial to Compare the Efficacy of elástic bandage 3M Coban™ 2 Lite against the Unna Boot in Patients with Leg Ulcers

Date of registration: 06/25/2019 ^(mm/dd/yyyy)
Last approval date : 06/25/2019 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effect of Laser therapy in dental trauma

Date of registration: 06/24/2019 ^(mm/dd/yyyy)
Last approval date : 06/24/2019 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Pulp repair response of primary teeth after the use of a new bandage

Date of registration: 06/24/2019 ^(mm/dd/yyyy)
Last approval date : 06/24/2019 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

The Effect of Diet on the Renal Function of Renal Transplant Patients: Nutritional Status and Quality of Life

Date of registration: 06/21/2019 ^(mm/dd/yyyy)
Last approval date : 06/21/2019 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

The effect of music therapy in the reduction of fatigue of the patients undergoing bone marrow transplantation

Date of registration: 06/21/2019 ^(mm/dd/yyyy)
Last approval date : 06/21/2019 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Motor Imagery and Rehabilitation in Temporomandibular disorders

Date of registration: 06/21/2019 ^(mm/dd/yyyy)
Last approval date : 06/21/2019 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Dental canal infections and Impact on Quality of Life

Date of registration: 06/21/2019 ^(mm/dd/yyyy)
Last approval date : 06/21/2019 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Observational

The effects of Geotherapy on Heartburn and Reflux Symptoms: pilot clinical trial

Date of registration: 06/21/2019 ^(mm/dd/yyyy)
Last approval date : 06/21/2019 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effects of exercise and athletic tape on the arm of stroke patients

Date of registration: 06/21/2019 ^(mm/dd/yyyy)
Last approval date : 06/21/2019 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

The use of Super Glue® in perineal laceration in birth

Date of registration: 06/21/2019 ^(mm/dd/yyyy)
Last approval date : 06/21/2019 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Intervention to improve tracking for people with HIV

Date of registration: 06/20/2019 ^(mm/dd/yyyy)
Last approval date : 06/20/2019 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Evaluation of Effects on Pain through the Use of Lidocaine Adhesive after Cesarean

Date of registration: 06/19/2019 ^(mm/dd/yyyy)
Last approval date : 06/19/2019 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Stereotactic ablation of Hypothalamic hamartomas for seizure treatment

Date of registration: 06/18/2019 ^(mm/dd/yyyy)
Last approval date : 06/18/2019 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Therapeutic toys in schoolchildren: reference values in plethysmography

Date of registration: 06/18/2019 ^(mm/dd/yyyy)
Last approval date : 06/18/2019 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Observational

Clinical investigation in deciduous teeth using Bulk Fill flow resin.

Date of registration: 06/12/2017 ^(mm/dd/yyyy)
Last approval date : 06/18/2019 ^(mm/dd/yyyy)
Last revision: 4

Study type:

Interventional

Movement and sensibility, financial condition and welfare state of person after suffering from stroke

Date of registration: 06/18/2019 ^(mm/dd/yyyy)
Last approval date : 06/18/2019 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Patient satisfaction and evaluation of the material to prepare the final smile test in aesthetic ceramic restorations.

Date of registration: 06/17/2019 ^(mm/dd/yyyy)
Last approval date : 06/17/2019 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

How physical training is able to improve chest pain in patients without coronary disease

Date of registration: 06/17/2019 ^(mm/dd/yyyy)
Last approval date : 06/17/2019 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effect of scalp acupuncture in patients with chronic stoke - randomized clinical trial

Date of registration: 06/17/2019 ^(mm/dd/yyyy)
Last approval date : 06/17/2019 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

A randomized clinical study using Mta for the treatment of canal on milk teeth

Date of registration: 06/17/2019 ^(mm/dd/yyyy)
Last approval date : 06/17/2019 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Username/Password

News

06/01/2026

Rede HU Brazil's first public stem cell biobank will operate under Humap-UFMS

06/01/2026 | HU Brazil Network | Gov.br

https://www.gov.br/hubrasil/pt-br/hospitais-universitarios/regiao-centro-oeste/humap-ufms/comunicacao/noticias/ebserh/primeiro-biobanco-publico-de-celulas-tronco-da-rede-hu-brasil-functurara-no-humap-ufms-1

Service opens the way for innovation in regenerative medicine and advanced therapies within SUS

The Maria Aparecida Pedrossian University Hospital, of the Federal University of Mato Grosso do Sul (Humap-UFMS), linked to HU Brasil, receives approval from the National Research Ethics Commission (Conep) for the operation of the mesenchymal stem cell biobank (CTM). Com isso, this unit will first be a public bank of samples of these types of cells, with a regulated flow of availability for research projects approved by the Committees of Ethics in Research with Human Beings.

According to Thais Farias, technical biologist in charge of the biobank and chef of the Humap Research Management Unit-UFMS, CTM is only cells that do not have a specific function, but can be found in specialized tissues, such as fat, umbilical cord, and dental pulp. leite. “They have the capacity to transform into other cells when they affect a healthy tissue, in addition to regulating the immune system in the areas of inflammation,” he explains.

Cells with regenerative potential

Due to these two characteristics reported by the biologist, CTM has potential for use in regenerative medicine and in the treatment of various diseases, such as arthritis, diabetes and neurological diseases. In addition to stem cells, the biobank also stores blood, serum and plasma samples, which broaden the scope of research for different areas of scientific knowledge.…

06/01/2026

Research from the Hospital da Rede HU Brasil in Niterói (RJ) highlights biological substances as a predisposing factor for cardiovascular diseases.

06/01/2026 | Paola Caracciolo | HU Brazil/MS Network | Gov.br

https://www.gov.br/hubrasil/pt-br/comunicacao/noticias/pesquisa-do-hospital-da-rede-hu-brasil-em-niteroi-rj-destaca-substancias-biologicas-como-fator-de-propensao-a-doencas-cardiovasculares

Biomarkers such as GDF-15 provide information for diagnosis and prognosis

Biomarkers are substances found in our blood or urine that can be used for the diagnosis of diseases. Researcher Humberto Villacorta (aside), professor of cardiology at Universidade Federal Fluminense and doctor at Hospital Universitário Antônio Pedro (Huap-UFF), reports on a line of studies that investigates the biomarker GDF-15 (Growth Differentiation Factor 15) as indicative of cardiovascular alterations.

"At the bottom of the line is the area of heart failure, which is a situation in which the heart grows and increases in size, often causes symptoms such as lack of heart and swelling in the legs. And within the heart doenças I study cardiac biomarkers, which contain substances that "People do not bleed or urine, and we provide information for diagnoses and prognoses, or seja, establish the risk of death or hospitalization of a certain condition," explains the researcher.

Humberto Villacorta says that among the most common biomarkers found in blood are natriuretic peptides (BNP and NT-proBNP) and troponins. Therefore, more recently, the growth factor of differentiation, or GDF-15, is gaining prominence in research around the world. GDF-15 is a cytokine, a protective cellular component, which has an anti-inflammatory function.

"We know that when the GDF-15 biomarker is high, it indicates a worse prognosis, but in some situations it can…

06/01/2026

Clinical Trial Shows Novel Prostate Cancer Treatment Can Reduce Risk of Disease Progression by Half

06/01/2026 | Huntsman Cancer Institute at the University of Utah | News Wise

https://www.newswise.com/articles/clinical-trial-shows-novel-prostate-cancer-treatment-can-reduce-risk-of-disease-progression-by-half

A Phase 3 clinical trial led by Neeraj Agarwal, MD, FASCO, senior director of clinical research at Huntsman Cancer Institute and professor of internal medicine at the University of Utah (the U), has found that a combination prostate cancer treatment could prevent the disease from progressing into a harder-to-treat form of cancer in select patients.

The study, TALAPRO-3 (NCT04821622), evaluated a combination of two drugs—talazoparib and enzalutamide—in patients with metastatic castration-sensitive prostate cancer. This is a form of the disease that has spread beyond the prostate but remains susceptible to standard hormone therapy treatment. The patients involved also had prostate cancer affected by certain gene mutations, including but not limited to BRCA1 and BRCA2 mutations, that often signal more aggressive disease.

Agarwal and his research team assessed enzalutamide in combination with talazoparib in comparison to enzalutamide alone, the standard of care. Using the two drugs together led to an observed 52% reduction in the risk of disease progression or death.

The results of the trial have been published in the prestigious New England Journal of Medicine. Agarwal also presented these findings as a late-breaking abstract at the American Society of Clinical Oncology Annual Meeting.

“Delaying progression to castration-resistant disease, when hormone therapy will no longer work, remains a significant challenge in patients with an earlier stage of metastatic prostate cancer, also known as castration-sensitive prostate…

06/01/2026

Clinical Trial Transparency Enforcement: A Practical Guide for Sponsors and Research Sites After FDA’s April 2026 Reminders

06/01/2026 | Mary L. Hendrickson/Emily K. Weber | Foley

https://www.foley.com/insights/publications/2026/06/clinical-trial-transparency-enforcement-a-practical-guide-for-sponsors-and-research-sites-after-fdas-april-2026-reminders/

On April 13, 2026, the U.S. Food & Drug Administration (FDA) publicly disclosed that it had sent targeted reminder messages on March 30, 2026, to more than 2,200 sponsors and researchers concerning over 3,000 registered clinical trials that appear to lack required results postings on ClinicalTrials.gov. The agency’s internal review indicated that nearly 30 percent of studies considered “highly likely” to be subject to mandatory reporting obligations still have no results available to the public. Former but then-current FDA Commissioner Marty Makary emphasized that the failure to report results distorts the scientific record by over-representing positive outcomes while concealing negative or inconclusive findings — a situation the agency views as a direct threat to public health and informed decision-making by patients, physicians, and regulators.

These reminders stem from long-standing statutory and regulatory requirements under Section 801 of the Food and Drug Administration Amendments Act of 2007 (FDAAA), codified at Public Health Service Act § 402(j) and FDA’s 2016 Final Rule implementing that provision (42 C.F.R. Part 11). In general, “applicable clinical trials” must have results submitted to ClinicalTrials.gov no later than one year after the trial’s primary completion date. The obligations apply regardless of whether the product ultimately receives marketing approval, and they extend to both positive and negative outcomes.

Although…

06/01/2026

Three Ebola Vaccine Candidates Fast-tracked, as Kenya Refuses US Quarantine Facility

06/01/2026 | Kerry Cullinan | Health Policy Watch

https://healthpolicy-watch.news/three-eboba-vaccine-candidates-fast-tracked/

Three investigational vaccine candidates for the Ebola Bundibugyo virus are being “urgently accelerated towards clinical trials”, the Coalition for Epidemic Preparedness Innovations (CEPI) announced on Monday.

There are no licensed vaccines for the Bundibugyo virus, and none are in clinical development. This is the strain of Ebola currently driving the outbreak in the Democratic Republic of Congo (DRC) and Uganda, with over 1000 suspected cases and 246 deaths.

CEPI will invest up to $62 million “to back a portfolio of candidates under development from longstanding partners with proven capabilities”.

These include candidates developed by IAVI, Moderna, and the University of Oxford, which will be manufactured at the Serum Institute of India.

IAVI has been awarded $3.2m to accelerate the development of a recombinant vesicular stomatitis virus (rVSV)-based vaccine candidate.

The candidate was developed by University of Texas Medical Branch (UTMB) scientist Dr Thomas Geisbert and colleagues, building on earlier work by Andrea Marzi and Heinz Feldmann from the National Institute for Allergy and Infectious Diseases in the United States.

IAVI has reached an agreement with UTMB to develop the rVSV candidate, which has “demonstrated protective efficacy in nonhuman primate studies but has not yet been evaluated in humans”, IAVI noted in a statement on Monday, adding that the Dutch government is assisting in financing the vaccine development.

World Health Organization (WHO) experts determined last week that IAVI’s one-dose rVSV vaccine candidate is the most promising Bundibugyo vaccine candidate in the pipeline and called for it…